ERBB2 and neoplasm: Because of the difference in pharmacological activity among types of endocrine therapy, it has been suggested in a neoadjuvant study that the choice of therapeutic agent might affect the responsiveness of HER2-overexpressing tumours (Ellis et al. 2001).